康美药业股份有限公司关于变更 签字注册会计师及项目质量控制复核合伙人的公告

Core Viewpoint - The company has appointed new auditors for the 2025 fiscal year, ensuring continuity and compliance in its financial reporting and internal control audits [1]. Group 1: Auditor Appointment - The company’s board approved the reappointment of Zhongshun Zhonghuan Accounting Firm as the auditor for the 2025 fiscal year [1]. - The signing auditors are Wu Zhihao and Sheng Peiyong, while Zhao Liang will serve as the quality control review partner [1]. Group 2: Auditor Background - Sheng Peiyong became a certified public accountant in 2022 and has been involved in auditing listed companies since 2012, starting to practice at Zhongshun Zhonghuan in 2024 [2]. - Zhao Liang became a certified public accountant in 2020 and has been auditing listed companies since 2018, also starting to practice at Zhongshun Zhonghuan in 2020 [2]. Group 3: Independence and Integrity - The newly appointed auditors and quality control review partner have no record of criminal or administrative penalties in the last three years [2]. - There are no violations of the independence requirements as per the Code of Ethics for Chinese Certified Public Accountants [3]. Group 4: Impact on the Company - The transition to the new auditors will be orderly, and it is not expected to adversely affect the company's financial reporting and internal control audit for 2025 [4].

KMYY-康美药业股份有限公司关于变更 签字注册会计师及项目质量控制复核合伙人的公告 - Reportify